Cornell Researchers Complete Kratom's Biosynthetic Pathway in Yeast, Opening Door to Pharmaceutical Production

Why it matters

By reconstructing kratom's alkaloid biosynthesis in yeast, researchers have created a scalable platform to study and potentially produce kratom-derived compounds without relying on the plant—accelerating drug discovery and enabling production of specific alkaloids like mitragynine for clinical research.

The big picture

Kratom contains over 50 unique alkaloids, but the plant's full biosynthetic pathway had never been mapped. The precursor molecule strictosidine is the universal starting point for all of these compounds, as well as for drugs like vincristine (cancer) and quinine (malaria). Understanding how kratom makes strictosidine unlocks the entire alkaloid family for engineering.

Key findings

• Cornell engineers used multiplex yeast pathway engineering to reconstruct the full kratom strictosidine biosynthesis from geranyl pyrophosphate and tryptophan
• The team identified 13 functional kratom genes enabling rapid validation of pathway modules
• A vacuolar secologanin transporter (MsNPF2.6) was identified that increased strictosidine production by 62% in yeast
• The work was funded by NIH and NSF and represents the first complete elucidation of the kratom strictosidine pathway
• The platform enables rapid discovery and optimization of plant natural product pathways beyond kratom

What they say

The researchers stated that the work establishes "the strictosidine pathway in kratom and highlights multiplex engineering as a powerful platform for rapid plant pathway discovery and optimization."

Bottom line

Cornell University researchers have engineered yeast to produce kratom's key biosynthetic precursor, potentially enabling pharmaceutical-grade production of kratom alkaloids for drug discovery without relying on plant cultivation.